80854-62-2

Upstream product

• 80854-57-5 3-(4-nitro-phenyl)-crotonic acid ethyl ester 
• 80854-59-7 β-methyl-4-nitrocinnamic acid 

Downstream Products

• 1332645-30-3 (R)-4-(4-nitrophenyl)-6-(trifluoromethyl)-6-phenyl-5,6-dihydro-2H-pyran-2-one 
• 1332645-66-5 (R)-1-benzyl-4'-(4-nitrophenyl)spiro[indoline-3,2'-pyran]-2,6'(1H,3'H)-dione 
• 1528764-88-6 (S)-ethyl 4-(4-nitrophenyl)-6-oxo-1-tosyl-1,2,3,6-tetrahydropyridine-2-carboxylate 
• 1581699-99-1 (R)-ethyl 4-(4-nitrophenyl)-6-oxo-1-tosyl-1,2,3,6-tetrahydropyridine-2-carboxylate 
• 1581700-02-8 (2S,4S)-ethyl 4-(4-aminophenyl)-6-oxo-1-tosylpiperidine-2-carboxylate 
• 1581700-16-4 (2R,4S)-ethyl 4-(4-aminophenyl)-6-oxo-1-tosylpiperidine-2-carboxylate 

Relevant academic research and scientific papers

Development of new scaffolds as reversible tissue transglutaminase inhibitors, with improved potency or resistance to glutathione addition

Previous studies within our group have yielded a class of cinnamoyl-based competitive reversible inhibitors for tissue transglutaminase (TG2), with Ki values as low as 1.0 μM (compound CP4d). However, due to the electrophilic nature of their al